EUVIMEDEUVIMED entdecken
Crossref

Asthma and Atopic Dermatitis in Asia, 1990–2021: The Global Burden of Disease Study 2021

GBD 2021 Asia Allergic Disorders Collaborators

Clinical & Experimental Allergy · 2025

DOI: 10.1111/cea.70024 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical & Experimental Allergy, 2025. Verfasst von GBD 2021 Asia Allergic Disorders Collaborators. Hauptthemen laut MEDLINE: Asthma, Dermatitis, Atopic, Global Burden of Disease. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: Gates Foundation, Bill and Melinda Gates Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Given the diverse population and regional differences across Asia, a comprehensive analysis of allergic diseases is crucial for guiding healthcare planning, resource allocation, and prevention strategies. Therefore, utilising the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021, we aimed to thoroughly investigate the burden of allergic conditions and their attributable risk factors in Asia.

Methods

Asthma and atopic dermatitis (AD) prevalence and burden estimates were calculated across various regions within Asia (Central, South, Southeast, East Asia and high‐income Asia Pacific) from 1990 to 2021, covering age groups segmented into five‐year intervals and analysing data separately and combined for males and females. The Bayesian meta‐regression tool was employed to estimate the prevalence, incidence, and cause‐specific mortality of allergic disorders. Asthma‐related deaths and disability‐adjusted life years (DALYs) attributable to each risk factor were estimated using relative risks, risk exposure and the theoretical minimum risk exposure level input.

Results

From 1990 to 2021, asthma in Asia showed significant declines in age‐standardised prevalence, mortality, and DALYs, exceeding global trends. In 2021, an estimated 106 million (95% UI, 92–121) individuals in Asia had asthma, with age‐standardised rates decreasing significantly. However, asthma‐related deaths still accounted for 346,755 (278,046–464,848) cases in 2021. In contrast, the AD burden remained stable, with 68.1 million (65.4–71.0) cases in 2021, reflecting a 16.1% increase since 1990, though the age‐standardised prevalence remained unchanged. AD exhibited the highest DALYs rates in high‐income Asia Pacific and Central Asia, with significant gender disparities in prevalence.

Conclusion

This study showed a declining age‐standardised asthma burden, mortality, and impact, along with a stable burden of AD in Asia from 1990 to 2021. This comprehensive data analysis would provide invaluable insights for making targeted health interventions and policies aimed at mitigating the burden of allergic diseases in Asia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaDermatitis, AtopicGlobal Burden of DiseaseHumansFemaleMaleAsiaPrevalenceChildAdultAdolescentMiddle AgedChild, PreschoolInfantRisk FactorsYoung AdultDisability-Adjusted Life YearsIncidenceAgedInfant, Newborn

Stichwörter der Autor:innen

AsiaGlobal Burden of Disease Injuries and Risk Factors Studyallergyasthmaatopic dermatitis

Förderung

  • Gates Foundation
  • Bill and Melinda Gates Foundation

Zitieren

APA

GBD 2021 Asia Allergic Disorders Collaborators (2025). Asthma and Atopic Dermatitis in Asia, 1990–2021: The Global Burden of Disease Study 2021. Clinical & Experimental Allergy. https://doi.org/10.1111/cea.70024

Vancouver

GBD 2021 Asia Allergic Disorders Collaborators. Asthma and Atopic Dermatitis in Asia, 1990–2021: The Global Burden of Disease Study 2021. Clinical & Experimental Allergy. 2025. doi:10.1111/cea.70024

BibTeX
@article{GBDAsiaAllergicDisordersCollaborators2025,
  author = {GBD 2021 Asia Allergic Disorders Collaborators, GBD 2021 Asia Allergic Disorders Collaborators},
  title = {Asthma and Atopic Dermatitis in Asia, 1990–2021: The Global Burden of Disease Study 2021},
  journal = {Clinical & Experimental Allergy},
  year = {2025},
  doi = {10.1111/cea.70024}
}
Kostenlos starten →